• How p38α Dephosphorylation Changes Kinase Inhibition

  2026-08-14

  The reference preprint shows that some kinase inhibitors can do more than occupy the p38α active site: they can stabilize an activation-loop conformation that accelerates WIP1-mediated dephosphorylation. This dual-action mechanism provides a structural framework for improving kinase inhibitor potency and specificity, while remaining distinct from evidence in cellular cytokine assays or disease models.

• TNF-alpha Recombinant Murine Protein in Cell-Death Mapping

  2026-08-14

  Explore how TNF-alpha recombinant murine protein can anchor reproducible apoptosis and inflammation assays while serving as a mechanistically distinct comparator for RNA Pol II degradation-dependent cell death. This guide connects product specifications with experimental design, pathway interpretation, and assay quality control.

• LTI6426 Enhances Panobinostat in Myeloma

  2026-08-13

  The reference study shows that the protein disulfide isomerase inhibitor LTI6426 markedly increases panobinostat activity in multiple myeloma models, including a proteasome inhibitor-resistant setting. Its central practical implication is that endoplasmic-reticulum stress may enable lower-dose panobinostat regimens, while ATF3, DDIT3/CHOP, and DNAJB1 emerge as candidate pharmacodynamic biomarkers.

• Phenacetin as a Translational PK Benchmark

  2026-08-13

  Phenacetin is more than a historical analgesic reference: its defined structure, limited water solubility, and safety constraints make it a useful stress test for translational pharmacokinetic workflows. This article connects Phenacetin assay strategy with the evidence architecture used in PDK4 inhibitor discovery, while clearly separating chemical benchmarking from target-specific pharmacology and clinical claims.

• LY364947: TGF-β Kinase Inhibition Workflows

  2026-08-12

  LY364947 provides a receptor-level way to dissect TGF-β signaling, Smad2 activation, EMT, fibrosis, and injury responses. This workflow-focused guide connects LY364947 with pancreatic cancer EMT research while emphasizing solvent handling, assay controls, quantitative readouts, and interpretation limits.

• HyperTrap Heparin HP Column for Protein Purification

  2026-08-12

  The HyperTrap Heparin HP Column is a preloaded affinity chromatography column for selective biomolecule purification. Its HyperChrom Heparin HP Agarose medium combines approximately 34 μm particles with a reported ligand density of approximately 10 mg/mL, while the polypropylene and HDPE construction supports routine laboratory handling.

• Dexamethasone (DHAP): Mechanism to Translation

  2026-08-11

  A translational framework for using Dexamethasone (DHAP) to connect inflammatory signaling, cell-state control, and model selection. The article integrates NF-κB biology, stem cell differentiation, neuroinflammation, and genetically informed cancer research without overstating what current evidence can prove.

• Cabazitaxel (XRP6258): Practical Assay Guide

  2026-08-11

  Cabazitaxel (XRP6258) is a semi-synthetic taxane derivative for studying microtubule dynamics disruption and antiproliferative responses in taxane-resistant cancer models. It is suited to carefully controlled DMSO- or ethanol-based workflows, but it is insoluble in water and prepared solutions should be used promptly rather than stored long term.

• iRhom2 in Olfaction: OR Regulation and Adaptation

  2026-08-10

  Azzopardi and colleagues identify iRhom2 as a distinctive component of olfactory sensory neurons and connect its expression to odorant receptor regulation and activity-dependent adaptation. The study combines mouse genetics, transcriptomics, spatial validation, and a heterologous receptor-signaling model to propose an iRhom2/ADAM17-linked negative-feedback mechanism.

• Radiotherapy, PD-1/TIGIT Blockade, and CD8+ Memory

  2026-08-09

  A 2025 Cancer Letters study shows that combining radiotherapy with PD-1 and TIGIT blockade can control both irradiated and distant tumors while establishing durable CD8+ T-cell memory in mouse models. Its integrated immune profiling links abscopal activity to activated CD8+ T cells, M1 macrophage signaling, and sustained cytokine communication, offering a mechanistic framework for cancer research on radioimmunotherapy resistance.

• AMPK–ULK1 Signaling in Energy Stress

  2026-08-08

  Park, Lee, and Kim challenge the prevailing view that AMPK uniformly activates ULK1 and autophagy during glucose deprivation. Their study shows that AMPK suppresses ULK1-dependent autophagy initiation during acute energy stress while preserving the autophagy machinery for recovery after stress subsides.

• LY364947: A Translational Lens on TGF-β and EMT

  2026-08-07

  LY364947 is a selective TGF-β type I receptor kinase inhibitor for dissecting Smad2 signaling, EMT, fibrosis, cancer biology, and retinal injury. This thought-leadership analysis connects direct receptor blockade with recent evidence that CDK4/6 and BET inhibition can reshape EMT through Wnt/β-catenin and TGF-β/Smad crosstalk, offering a framework for more rigorous translational study design.

• IPR-803: Advancing Tumor Stroma Modulation in Cancer Researc

  2026-08-07

  Explore how IPR-803, a potent urokinase receptor inhibitor, redefines strategies for inhibiting tumor invasion and enhancing chemotherapy in breast and pancreatic cancer models. This article offers a deep dive into stroma-targeted mechanisms, protocol guidance, and the translational value for oncology research.

• Resazurin Sodium Salt: Next-Generation Redox Indicator in Tr

  2026-08-06

  Explore the mechanistic power and strategic value of Resazurin sodium salt as a fluorogenic oxidation-reduction indicator in cell-based translational research. This article bridges foundational biochemistry with advanced assay design, referencing recent breakthroughs in Wnt/β-catenin pathway targeting and highlighting best practices for robust, high-throughput viability and cytotoxicity assessment. APExBIO's Resazurin sodium salt empowers researchers to optimize data quality and accelerate therapeutic innovation.

• IGF2BP1-m6A-TUBB4B Axis Drives Hepatic Stellate Cell Activat

  2026-08-06

  This study reveals that the m6A reader IGF2BP1 promotes hepatic stellate cell activation and liver fibrosis via stabilization of TUBB4B mRNA in an m6A-dependent manner. These findings establish the IGF2BP1/TUBB4B/FAK axis as a mechanistic driver of fibrogenesis and suggest new molecular targets for antifibrotic research.

16088 records 1/1073 page Next 12345 下5页 Last page